Rate My Professor Ben Forbes

The core of Professor Forbes’ research specializations includes the formulation of inhaled medicines, development and application of techniques to study respiratory drug transport and metabolism, and inhalation toxicology. As head of the Medicines Development Research Group, his team advances novel materials, formulations, drug delivery devices, manufacturing processes, analytical methods, and digital technologies essential for medicine development. He also participates in the Antimicrobial Research Theme. Forbes originated the term ‘Inhalation Biopharmaceutics’ to define the discipline addressing factors that influence respiratory and systemic exposure to inhaled drugs. His key publications encompass 'Pulmonary delivery of LNP-mRNAs aerosolised by vibrating mesh nebuliser' (2025), 'Particulate bioaerogels for respiratory drug delivery' (2024), 'A Design of Experiments Approach to Identify Critical Processing Parameters' (2025), 'The Use of Natural Polysaccharides in Spray-dried Microparticles' (2024), and 'Improving drug delivery for Alzheimer’s disease through nose-to-brain transport' (2021). He chairs the Scientific Advisory Committee of the Aerosol Society’s annual Drug Delivery to the Lung conference, contributes to pharmacy education, and supports the development of medicines for clinical evaluation, including recent advances in chemotherapy restoration for resistant cancers and optimised experimental designs.